|
Curran Jr, W J; Scott, C B; Weinstein, A S et al. (1993) Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 11:857-62
|
|
Byhardt, R W; Pajak, T F; Emami, B et al. (1993) A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys 26:459-68
|
|
Nelson, D F; Curran Jr, W J; Scott, C et al. (1993) Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25:193-207
|
|
Curran Jr, W J; Scott, C B; Horton, J et al. (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-10
|
|
Curran Jr, W J; Scott, C B; Nelson, J S et al. (1992) A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02. Cancer 70:2909-17
|
|
Curran Jr, W J; Scott, C B; Horton, J et al. (1992) Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 12:219-27
|
|
Curran Jr, W J; Cox, J D; Azarnia, N et al. (1991) Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protoc Cancer 68:509-16
|
|
Cox, J D; Azarnia, N; Byhardt, R W et al. (1990) A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-ce J Clin Oncol 8:1543-55
|
